Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

This study has been completed.
Information provided by (Responsible Party):
Teva Pharma Identifier:
First received: March 14, 2012
Last updated: April 22, 2016
Last verified: April 2016

This is an open, multicentre, prospective observational (non-interventional) study, performed in Belgium.

Principal objectives:

  1. To evaluate the prevalence of cardiovascular risk factors and cardiac function (as routinely evaluated) before treatment with anthracyclines of patients with metastatic breast cancer (MBC) aged > or = 65 years
  2. To observe the management of cardiovascular risk during and after anthracycline treatment
  3. To compare liposomal versus non-liposomal anthracycline therapy (ratio 1:1) on cardiac function, outcome and quality of life (EORTC QLQ-C30)

Secondary objectives:

  1. To evaluate the efficacy of anthracyclines on progression free survival and tumor response as routinely measured (e.g. recist criteria, tumor markers and other exams)
  2. To evaluate cardiovascular event type: ECG changes, arrhythmia, decrease of ejection fraction, heart failure and rate according to allocated treatment.
  3. To find out how quality of life, e.g. such as described according to EORTC QLQ-C30 criteria or Karnofsky index is achieved in the various patient subgroups
  4. To correlate the therapeutic choice and posology of anthracyclines for MBC with Cardiovascular risk at baseline
  5. To calculate the cardiovascular risk according to SCORE

Metastatic Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Screening and Management of Cardiovascular Risk in Belgian Women Aged > or = 65 Years With Metastatic Breast Cancer Before and After Anthracycline Treatment

Resource links provided by NLM:

Further study details as provided by Teva Pharma:

Primary Outcome Measures:
  • cardiovascular risk factors [ Time Frame: 15 months ]

Enrollment: 60
Study Start Date: February 2012
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Detailed Description:

The physician will be requested:

  • To include 15 consecutive patients aged > or = 65 years who will be treated with anthracyclines in first and second line MBC. The physician will be encouraged to enrol 2 arms of 8 patients (one treated with liposomal and one with non-liposomal anthracyclines) for observation and comparison. Each arm will be closed as soon as 150 patients are included at a national level.
  • To report their cardiovascular risk factors
  • To provide the results of routinely performed cardiac evaluation before treatment
  • To monitor routinely cardiovascular parameters during treatment and report them afterwards
  • To monitor efficacy and tolerance of treatments, as normal practice prescribes, reported and related to the variables described in objectives
  • To ensure that quality of life will be assessed with the EORTC QLQ-C30 questionnaire
  • To monitor and report progression free survival and cardiac events
  • To record and transmit spontaneously reported adverse events. These will be handled according to legal requirements

Follow-up will cover a period of 15 months following inclusion.

The study will have 3 visits and 2 contacts:

  • One visit at entry
  • One visit after 3 cycles of anthracycline containing therapy
  • One visit at the end of treatment
  • Contact at 9 months after inclusion
  • Contact at 15 months after inclusion

It is planned to include data from 15 consecutive female patients per specialized center in Belgium.

The total number of patients aimed is 300.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Belgian women aged > or = 65 years with metastatic breast cancer before and after anthracycline treatment.

Patients will be included in 24 centers specialized in the treatment of breast cancer, in Belgium.


Inclusion Criteria:

  • women aged 65 years old or more
  • with confirmed metastatic breast cancer (MBC)
  • who will be treated with anthracyclines in first or second line
  • who have a Karnofsky score at baseline of 50
  • who agree and are able to fill in the EORTC QLQ-C30 questionnaire
  • who gave their informed consent

Exclusion Criteria:

  • women having contra-Indications for anthracyclines
  • women aged < 65 years old
  • with no metastatic breast cancer
  • who will not be eligible for an anthracycline treatment in first or second line MBC
  • who have a Karnofsky less than 50
  • who disagree or are unable to fill in the EORTC QLQ-C30 questionnaire
  • women refusing or not having signed their informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01555944

ZNA Middelheim
Antwerp, Belgium, 2020
Cliniques du Sud Lux - St Joseph
Arlon, Belgium, 6700
Bonheiden, Belgium, 2820
Clinique Saint-Luc
Bouge, Belgium, 5004
Brasschaat, Belgium, 2930
AZ St Jan
Brugge, Belgium, 8000
CHU Brugmann
Brussels, Belgium, 1020
Brussels, Belgium, 1070
CHIREC - Centre Hospitalier Interrégional Edith Cavell
Brussels, Belgium, 1180
UZ Brussel
Brussel, Belgium, 1090
Chimay, Belgium, 6460
AZ St-Maarten
Duffel, Belgium, 2570
Edegem, Belgium, 2650
AZ St-Dimpna
Geel, Belgium, 2440
AZ St-Lucas
Ghent, Belgium, 9000
ZNA Jan Palfijn
Merksem, Belgium, 2170
Namur, Belgium, 5000
Namur, Belgium, 5000
AZ Damiaan
Oostende, Belgium, 8400
Clinique St Pierre
Ottignies, Belgium, 1340
AZ Nikolaas
St-Niklaas, Belgium, 9100
Centre Hospitalier de Wallonie picarde - site IMC
Tournai, Belgium, 7500
Verviers, Belgium, 4800
CHU Mont-Godinne
Yvoir, Belgium, 5530
Sponsors and Collaborators
Teva Pharma
Principal Investigator: Christel Fontaine, MD Universitair Ziekenhuis Brussel
  More Information

Responsible Party: Teva Pharma Identifier: NCT01555944     History of Changes
Other Study ID Numbers: MyCard
Study First Received: March 14, 2012
Last Updated: April 22, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on April 27, 2017